NV3P logo

NanoViricides DB:NV3P Stock Report

Last Price

€1.22

Market Cap

€18.6m

7D

0.8%

1Y

13.0%

Updated

02 Dec, 2024

Data

Company Financials +

NV3P Stock Overview

A clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. More details

NV3P fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

NanoViricides, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NanoViricides
Historical stock prices
Current Share PriceUS$1.22
52 Week HighUS$3.02
52 Week LowUS$0.90
Beta0.97
11 Month Change-4.69%
3 Month Change-29.07%
1 Year Change12.96%
33 Year Change-69.39%
5 Year Changen/a
Change since IPO-97.45%

Recent News & Updates

Recent updates

Shareholder Returns

NV3PDE BiotechsDE Market
7D0.8%1.9%1.5%
1Y13.0%-15.1%8.8%

Return vs Industry: NV3P exceeded the German Biotechs industry which returned -16.1% over the past year.

Return vs Market: NV3P exceeded the German Market which returned 7.8% over the past year.

Price Volatility

Is NV3P's price volatile compared to industry and market?
NV3P volatility
NV3P Average Weekly Movement11.9%
Biotechs Industry Average Movement6.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.9%
10% least volatile stocks in DE Market2.4%

Stable Share Price: NV3P's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: NV3P's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
20057Anil Diwanwww.nanoviricides.com

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company’s product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia.

NanoViricides, Inc. Fundamentals Summary

How do NanoViricides's earnings and revenue compare to its market cap?
NV3P fundamental statistics
Market cap€18.58m
Earnings (TTM)-€9.00m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NV3P income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$9.45m
Earnings-US$9.45m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.66
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did NV3P perform over the long term?

See historical performance and comparison